News | June 22, 2022
MedC Biopharma partners with A2W Pharma to develop cannabinoid therapeutics
Bringing next-gen cannabinoid therapeutics to cancer patients
Bringing next-gen cannabinoid therapeutics to cancer patients
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Both manufacturing facilities are based out of Benguluru, India
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
The nadAROSE and nadia3D kits address the needs of researchers exploring both agarose encapsulation and collagen-based hydrogel projects for the 3D cell culture space.
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Subscribe To Our Newsletter & Stay Updated
